Kane Biotech Inc.

Kane Biotech Inc.

December 18, 2006 09:03 ET

Kane Biotech Announces New Publication of Scientific Research

WINNIPEG, MANITOBA--(CCNMatthews - Dec. 18, 2006) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms, is pleased to announce the publication of a research paper on one of the company's new biofilm-inhibiting antimicrobial compositions. The paper appeared in a recent edition of the online Journal of Applied Microbiology, a peer-reviewed official Journal of the Society of Applied Microbiology (UK), dedicated to advances in the field of Applied Microbiology.

The publication, entitled "Effect of ovotransferrin, protamine sulfate and EDTA combination on biofilm formation by catheter-associated bacteria" authored by members of Kane Biotech's Research & Development team, demonstrates that the combination of the non-antibiotic compounds ovotransferrin (OT), protamine sulfate (PS) and ethylenediaminetetraacetic acid (EDTA) in a relatively low concentration was effective in reducing biofilm formation by catheter-associated bacteria. The paper is currently available on the Company's website, and is expected to be available in print early in 2007.

"We continue to advance our discoveries and expand our pipeline of antimicrobial products that prevent and disperse bacterial biofilms" stated Mr. Gord Froehlich, President of Kane Biotech Inc. "The publication of our studies continues to strengthen our reputation as a leading biofilm research team."

Kane Biotech continues to actively pursue commercialization of its lead anti-microbial catheter coating products, KBI-5898 and KBI-4258. These products have the potential to significantly reduce the occurrence of catheter related infections, a growing problem that costs the US healthcare system billions of dollars annually. Catheter associated urinary tract infections account for 40% of all hospital-acquired infections and catheter-related bloodstream infections associated with the use of central venous catheters are a major source of morbidity in the US.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay. An estimated 80% of all human infections involve biofilms.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information